Session I

Genomic landscapes

CLL and genomics
E. Campo
The role of microRNA in CLL pathogenesis
C.M. Croce
Predictive biomarkers
D. Rossi
Linking the microenviroment with CLL models
N. Chiorazzi
Biology of Richter syndrome
D. Rossi
Lecture

Introduction by C.M. Croce

Session II

Current initial treatment

Critical assessment and new development of prognostic scoring systems
D. Rossi
Is there still a role for the conventional chemoimmunotherapy?
C. Wendtner
New version of Fludarabine-containing regimen
M.S. Davids
How to treat older patients?
F. Bosch
Session III

Novel targeted therapies

Ibrutinib
S. O’Brien
Newer targeted treatments
A.D. Zelenetz
Zanubrutinib plus venetoclax
A. Tedeschi
Acalabrutinib plus venetoclax
M.S. Davids
Lecture

Introduction by A. Tedeschi

Session V

Newer agents

Pirtobrutinib
A.R. Mato
Session VI

Interesting observations/questions

Treatment-Naïve CLL: lessons from phase II and phase III clinical trials
S. O’Brien
Development of resistance to B-Cell Receptor inhibition
F. Bosch
What is the primary role of fixed-duration therapy? Should it be the main approach for (all) next-generation combination approaches or only for venetoclax-based combinations?
M.S. Davids
Privacy Policy | Cookie Policy